Open Label Extension Study of Nalbuphine HCl ER in Patients With Prurigo Nodularis

An Open Label Extension Study of the Safety and Anti-Pruritic Efficacy of Nalbuphine HCl ER Tablets in Prurigo Nodularis Patients

The primary objective of the study is to evaluate the overall safety of nalbuphine HCL ER tablets during a treatment period of up to 50 weeks.

Inclusion Criteria:

• Subject completed participation in the TR03 study

Exclusion Criteria:

• Medical condition or other factors that in the opinion of the Investigator may interfere with the conduct of the study.
• Subject is a pregnant or lactating female